Diligence memo · auto-generated · as of July 2, 2026

FinalDose

FinalDose: limited disclosed financing to assess.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

FinalDose is a private company, based in London, United Kingdom. Programmable DNA drug destroying all cancers, unlocking 80% of targets

Sub-sector tags: Artificial Intelligence, Gene Therapy, Therapeutics, Genetic Engineering.

Capital & rounds (filed)filed

FinalDose has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.

Valuation (modeled)modeled

No modeled valuation — too little disclosed financing to estimate one.

Financing rhythm & timingmixed

Not enough dated financing history to read a financing rhythm.

Comparablesmixed

Capital scale ranks ahead of 96% of sector peers (8525 compared).

Modeled value ranks above 96% of those peers.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.